Orelabrutinib

Orelabrutinib
Clinical data
Trade names	宜诺凯
Other names	ICP-022; ICP022
ATC code	L01EL04 ( WHO );
Legal status
Legal status	In general: ℞ (Prescription only);
Identifiers
	IUPAC name 2-(4-Phenoxyphenyl)-6-(1-prop-2-enoylpiperidin-4-yl)pyridine-3-carboxamide;
CAS Number	1655504-04-3 ;
PubChem CID	91667513 ;
IUPHAR/BPS	10629 ;
DrugBank	DB16272 ;
ChemSpider	82956396 ;
UNII	WJA5UO9E10 ;
ChEMBL	ChEMBL4650321 ;
Chemical and physical data
Formula	C26H25N3O3
Molar mass	427.504 g·mol−1
3D model (JSmol)	Interactive image ;
	SMILES C=CC(=O)N1CCC(CC1)C2=NC(=C(C=C2)C(=O)N)C3=CC=C(C=C3)OC4=CC=CC=C4;
	InChI InChI=1S/C26H25N3O3/c1-2-24(30)29-16-14-18(15-17-29)23-13-12-22(26(27)31)25(28-23)19-8-10-21(11-9-19)32-20-6-4-3-5-7-20/h2-13,18H,1,14-17H2,(H2,27,31); Key:MZPVEMOYADUARK-UHFFFAOYSA-N;

Last updated January 01, 2026

Orelabrutinib is a drug for the treatment of cancer.

In China, it is approved for patients with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), who have received at least one treatment in the past.^[1]

Orelabrutinib is an inhibitor of Bruton's tyrosine kinase.^[2]

References

↑ Dhillon S (March 2021). "Orelabrutinib: First Approval". Drugs. 81 (4): 503–507. doi:10.1007/s40265-021-01482-5. PMID 33704654.
↑ Deng LJ, Zhou KS, Liu LH, Zhang MZ, Li ZM, Ji CY, et al. (August 2023). "Orelabrutinib for the treatment of relapsed or refractory MCL: a phase 1/2, open-label, multicenter, single-arm study". Blood Advances. 7 (16): 4349–4357. doi:10.1182/bloodadvances.2022009168. PMC 10432605 . PMID 37078706.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.

[1] Dhillon S (March 2021). "Orelabrutinib: First Approval". Drugs. 81 (4): 503–507. doi:10.1007/s40265-021-01482-5. PMID 33704654.

[2] Deng LJ, Zhou KS, Liu LH, Zhang MZ, Li ZM, Ji CY, et al. (August 2023). "Orelabrutinib for the treatment of relapsed or refractory MCL: a phase 1/2, open-label, multicenter, single-arm study". Blood Advances. 7 (16): 4349–4357. doi:10.1182/bloodadvances.2022009168. PMC 10432605 . PMID 37078706.

[1]

[2]